T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
ICF International
ICFI
$1.59B
| $1.59M | ﹤0.01% |
18,641
+1,772
| +11% | +$150K |
|
1852
Westamerica Bancorp
WABC
$1.39B
| $1.59M | ﹤0.01% |
33,177
+4,322
| +15% | +$207K |
|
|
DVAX
1853
DELISTED
Dynavax Technologies
DVAX
| $1.58M | ﹤0.01% |
102,996
+4,909
| +5% | +$54.1K |
|
|
ELME
1854
Elme Communities
ELME
$144M
| $1.58M | ﹤0.01% |
91,091
+3,127
| +4% | +$53K |
|
1855
Ziff Davis
ZD
$1.9B
| $1.58M | ﹤0.01% |
44,890
+250
| +0.6% | +$8.72K |
|
1856
Pilgrim's Pride
PPC
$6.57B
| $1.58M | ﹤0.01% |
40,404
-2,084
| -5% | -$80.1K |
|
1857
United Fire Group
UFCS
$1.39B
| $1.57M | ﹤0.01% |
43,257
-8,675
| -17% | -$297K |
|
1858
Worthington Enterprises
WOR
$2.87B
| $1.57M | ﹤0.01% |
30,501
+1,424
| +5% | +$78.6K |
|
1859
Garrett Motion
GTX
$5.44B
| $1.57M | ﹤0.01% |
90,060
+17,975
| +25% | +$286K |
|
1860
World Kinect Corp
WKC
$1.86B
| $1.57M | ﹤0.01% |
66,857
+6,529
| +11% | +$161K |
|
1861
Progyny
PGNY
$2.01B
| $1.56M | ﹤0.01% |
60,925
-6,429
| -10% | -$148K |
|
1862
Iridium Communications
IRDM
$5.29B
| $1.56M | ﹤0.01% |
89,910
-15,316
| -15% | -$271K |
|
1863
Triumph Financial Inc
TFIN
$1.87B
| $1.56M | ﹤0.01% |
24,888
+3,606
| +17% | +$202K |
|
1864
Diebold Nixdorf
DBD
$2.47B
| $1.55M | ﹤0.01% |
22,870
-586
| -2% | -$36.6K |
|
1865
Harmony Biosciences
HRMY
$2.22B
| $1.55M | ﹤0.01% |
41,459
+5,011
| +14% | +$165K |
|
1866
Century Communities
CCS
$2.01B
| $1.55M | ﹤0.01% |
26,119
+1,240
| +5% | +$75.5K |
|
|
UMH
1867
UMH Properties
UMH
$1.41B
| $1.55M | ﹤0.01% |
97,373
+13,520
| +16% | +$203K |
|
1868
Albany International
AIN
$1.82B
| $1.55M | ﹤0.01% |
30,487
+5,139
| +20% | +$266K |
|
1869
Innoviva
INVA
$1.52B
| $1.54M | ﹤0.01% |
77,179
+4,722
| +7% | +$92.2K |
|
|
ARR
1870
Armour Residential REIT
ARR
$2.38B
| $1.53M | ﹤0.01% |
86,494
+579
| +0.7% | +$9.61K |
|
1871
Enovis
ENOV
$1.52B
| $1.53M | ﹤0.01% |
57,444
+2,535
| +5% | +$74.9K |
|
1872
Sunstone Hotel Investors
SHO
$2.03B
| $1.52M | ﹤0.01% |
169,879
+7,043
| +4% | +$64.6K |
|
|
GRSD
1873
Grandstand Limited Ordinary Shares
GRSD
$77.2M
| $1.52M | ﹤0.01% |
277,719
+20,349
| +8% | +$129K |
|
1874
Southside Bancshares
SBSI
$985M
| $1.52M | ﹤0.01% |
49,926
+10,238
| +26% | +$300K |
|
1875
First Financial Corp
THFF
$978M
| $1.52M | ﹤0.01% |
25,117
+8,442
| +51% | +$486K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.